LGALS3 and asthma: Gal-3 has been suggested as a reliable biomarker to predict the modulation of airway remodeling in severe asthma patients before they begin omalizumab therapy (133) and selective Gal-3 antagonists/inhibitors that are effective in attenuating lung fibrosis have been developed that are currently in preclinical or phase I testing.